An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C

The purpose of this open-label, non-randomized, single-arm, multicentre observational study is to investigate the influence of the cumulative dose (total administered dose/ planned dose) of ribavirin on the sustained virologic response (SVR) in participants who have been receiving combination therapy with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copegus).

Inclusion Criteria:

• Participants with serologically confirmed chronic hepatitis C
• Participants using and accepting a double method of contraception

Exclusion Criteria:

• Participants not approved by the national treatment guideline or the Interferon Committee for combined pegylated interferon-ribavirin treatment
• Contraindications in the summary of product characteristics of pegylated interferon alpha-2a and ribavirin
• Participants previously treated with pegylated interferon and/or ribavirin
• Hepatitis B and Human Immunodeficiency Virus co-infections